201 related articles for article (PubMed ID: 33001279)
1. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
Moore DC; Nelson V; Muslimani A
Ann Hematol; 2021 Dec; 100(12):3053-3055. PubMed ID: 33001279
[No Abstract] [Full Text] [Related]
2. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
3. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ
Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
[No Abstract] [Full Text] [Related]
5. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
DiNardo C
Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
7. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
8. Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
Maral S; Albayrak M; Sahin O; Ozturk HBA; Han U; Falay M
J Oncol Pharm Pract; 2021 Mar; 27(2):464-469. PubMed ID: 33620259
[TBL] [Abstract][Full Text] [Related]
9. Molecular remission and response patterns in patients with mutant-
Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
[TBL] [Abstract][Full Text] [Related]
10. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
11. Enasidenib for the treatment of acute myeloid leukemia.
Dugan J; Pollyea D
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
[TBL] [Abstract][Full Text] [Related]
12. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L; David MD; Kennedy A; Metzner M; Amatangelo M; Shih A; Stoilova B; Quivoron C; Heiblig M; Willekens C; Saada V; Alsafadi S; Vijayabaskar MS; Peniket A; Bernard OA; Agresta S; Yen K; MacBeth K; Stein E; Vassiliou GS; Levine R; De Botton S; Thakurta A; Penard-Lacronique V; Vyas P
Nat Med; 2018 Aug; 24(8):1167-1177. PubMed ID: 30013198
[TBL] [Abstract][Full Text] [Related]
13. Targeting the
Amaya ML; Pollyea DA
Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
15. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
[TBL] [Abstract][Full Text] [Related]
16. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
17. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM
Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone].
Wang DY; Cui YS; Liu YZ; Liu LN; Song YP; Fang BJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):463. PubMed ID: 27431068
[No Abstract] [Full Text] [Related]
19. A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.
Kats LM; Vervoort SJ; Cole R; Rogers AJ; Gregory GP; Vidacs E; Li J; Nagaraja R; Yen KE; Johnstone RW
Leukemia; 2017 Jun; 31(6):1466-1470. PubMed ID: 28280273
[No Abstract] [Full Text] [Related]
20. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
[Next] [New Search]
